Positron emission tomography for staging and management of malignant melanoma

British Journal of Surgery

Volumn 89, Issue 4, 2002, Pages 389-396

  Prichard, R S ^a   Hill, A D K ^a   Skehan, S J ^a   O'Higgins, N J ^a  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER DIAGNOSIS; CANCER STAGING; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; HUMAN; INTERMETHOD COMPARISON; LUNG METASTASIS; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MEDLINE; MELANOMA; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; THORAX RADIOGRAPHY; TUMOR VOLUME;

FLUORODEOXYGLUCOSE F18; HUMANS; MELANOMA; NEOPLASM STAGING; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0036267798     PISSN: 00071323     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0007-1323.2002.02059.x     Document Type: Review

References (60)

1. Cancer statistics, 1996
2. Epidemiology of malignant melanoma, worldwide incidence, and etiologic factors
3. Malignant melanoma in the 1990s: The continued importance of early detection and the role of physician examination and self-examination of the skin
4. Cancer statistics, 1994
5. Cutaneous malignant melanoma and sun exposure. Recent developments in epidemiology
6. Epidemiology of malignant melanoma
7. Malignant melanoma: Pattern of metastasis
8. Metastatic melanoma. A clinicopathological study
9. Cutaneous melanoma
10. Results of treatment of 269 patients with primary cutaneous melanoma: A five-year prospective study
11. A multifactorial analysis of melanoma. III. Prognostic factors in melanoma patients with lymph node metastases (stage II)
12. Local and transit metastases following definitive excision for primary cutaneous malignant melanoma
13. Technical details of intraoperative mapping for early stage melanoma
14. Staging of melanoma
15. Role of computed tomography in staging of primary melanoma
16. 18F]fluorodeoxyglucose and positron emission tomography
17. On the metabolism of tumours in the body
18. 14C]deoxyglucose method for the measurement of local cerebral glucose utilization: Theory, procedure, and normal values in the conscious and anaesthetized albino rat
19. A fluorinated glucose analog, 2-fluoro-2-deoxy-D-glucose (F-18): Nontoxic tracer for rapid tumor detection
20. Influence of the blood glucose concentration on FDG uptake in cancer: A PET study
21. Positron emission tomography in oncology. General acceptance of its role is overdue
22. Performance characteristics of a whole-body PET scanner
23. Whole-body positron emission tomography: Part 1. Methods and performance characteristics
24. Uptake of carbon-11-methionine and fluorodeoxyglucose in non-Hodgkin's lymphoma: A PET study
25. Positron emission tomography: A new, precise imaging modality for detection of primary head and neck tumors and assessment of cervical adenopathy
26. Recurrence of colorectal tumors: A PET evaluation
27. 18F]FDG positron emission tomography
28. PET evaluation of soft-tissue masses with fluorine-18 fluoro-2-deoxy-D-glucose
29. Lung tumor imaging by positron emission tomography using C-11 L-methionine
30. Standardized uptake values of normal tissues at PET with 2[fluorine-18]-fluoro-2-deoxy-D-glucose: Variations with body weight and a method for correction
31. Initial assessment of positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose in the imaging of malignant melanoma
32. Malignant melanoma: Staging with whole body positron emission tomography and 2-[F-18]-fluoro-2-D-glucose
33. Staging of metastatic melanoma by whole-body positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose
34. Positron emission tomography and ultrasonography. A comparative study assessing the diagnostic validity in lymph node metastasis of malignant melanoma
35. Positron emission tomography in the detection and management of metastatic melanoma
36. Initial assessment of positron emission tomography for detection of nonpalpable regional lymphatic metastases in melanoma
37. Primary staging and follow-up of high risk melanoma patients with whole body 18-fluorodeoxyglucose positron emission tomography: Results of a prospective study of 100 patients
38. Effectiveness of positron emission tomography for detection of melanoma metastases
39. 18F]-2-deoxy-D-glucose positron emission tomography in staging of regional lymph nodes in patients with cutaneous malignant melanoma
40. The value of positron emission tomography scanning in the detection of subclinical metastatic melanoma
41. Malignant melanoma staging using whole-body positron emission tomography
42. Positron emission tomography scanning in malignant melanoma
43. Axillary node dissection in malignant melanoma: Results and complications
44. Prospective study of fluorodeoxyglucose-positron emission tomography imaging of lymph node basins in melanoma patients undergoing sentinel node biopsy
45. Technical details of intraoperative lymphatic mapping for early stage melanoma
46. Lymphoscintigraphy in high-risk melanoma of the trunk: Predicting draining node groups, defining lymphatic channels and locating the sentinel node
47. The impact of dynamic lymphoscintigraphy and gamma probe guidance on sentinel node biopsy in melanoma
48. The orderly progression of melanoma nodal metastases
49. Prognostic significance of the sentinel node (SLN) in stage I or II melanoma patients
50. Prognostic evaluation of sentinel node biopsy
51. Whole-body positron emission tomography: An accurate staging modality for metastatic melanoma
52. PET in oncology: Will it replace other modalities?
53. Cost-effectiveness of PET imaging in clinical oncology
54. 18F-2-deoxy-2-fluoro-D-glucose uptake into human tumour xenografts. Feasibility studies for cancer imaging with positron emission tomography
55. 18F]-fluorodeoxy-glucose uptake in abdominal abscesses: A PET study
56. 18F-2-fluoro-2-deoxy-D-glucose in infection and in reactive lymph nodes
57. 18F]-D-glucose (FDG) for the detection of tumor involvement in lymph nodes